We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Ascending
  • Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update

     -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or metastatic squamous cellRead More

  • Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors

    Entrepreneurial leader brings expertise growing biotech platform companies  BOSTON and ROCKVILLE, Md. , April 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics forRead More

In the News

Sorting:
Sort Ascending
  • Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update

     -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or metastatic squamous cellRead More

  • Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors

    Entrepreneurial leader brings expertise growing biotech platform companies  BOSTON and ROCKVILLE, Md. , April 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics forRead More

Signup For Update

sign up for newsletter and get the latest update